US20070212770A1 - Oligopeptide-free cell culture media - Google Patents

Oligopeptide-free cell culture media Download PDF

Info

Publication number
US20070212770A1
US20070212770A1 US11/649,694 US64969407A US2007212770A1 US 20070212770 A1 US20070212770 A1 US 20070212770A1 US 64969407 A US64969407 A US 64969407A US 2007212770 A1 US2007212770 A1 US 2007212770A1
Authority
US
United States
Prior art keywords
cells
virus
cell culture
oligopeptide
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/649,694
Other languages
English (en)
Inventor
Leopold Grillberger
Manfred Reiter
Wolfgang Mundt
Artur Mitterer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37942126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070212770(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to US11/649,694 priority Critical patent/US20070212770A1/en
Assigned to BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC. reassignment BAXTER HEALTHCARE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUNDT, WOLFGANG, GRILLBERGER, LEOPOLD, MITTERER, ARTUR, REITER, MANFRED
Publication of US20070212770A1 publication Critical patent/US20070212770A1/en
Priority to US13/035,696 priority patent/US20110151512A1/en
Assigned to BAXTER INTERNATIONAL INC., BAXTER HEATHCARE S.A. reassignment BAXTER INTERNATIONAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUNDT, WOLFGANG, GRILLBERGER, LEOPOLD, MITTERER, ARTUR, REITER, MANFRED
Priority to US14/942,771 priority patent/US9758568B2/en
Priority to US15/670,217 priority patent/US10696731B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine.
  • the invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.
  • FCS fetal calf serum
  • serum or serum-derived substances such as, e.g., albumin, transferrin or insulin
  • serum or serum-derived substances may comprise unwanted agents that can contaminate the cell cultures and the biological products obtained thereof.
  • human serum derived additives have to be tested for all known viruses, including hepatitis viruses and HIV which can be transmitted via serum.
  • bovine serum and products derived thereof bear the risk of BSE contamination.
  • all serum-derived products can be contaminated by unknown substances.
  • Such serum-free media have been developed on the basis of protein extracts derived from plants or yeast.
  • soy hydrolysates are known to be useful for fermentation processes and can enhance the growth of many fastidious organisms, yeasts and fungi.
  • WO 96/26266 describes that papaic digests of soy meal are a source of carbohydrate and nitrogen and many of the components can be used in tissue culture.
  • Franek et al. Biotechnology Progress (2000) 16, 688-692 describe growth and productivity promoting effects of defined soy and wheat hydrolysate peptide fractions.
  • WO 96/15231 discloses a serum-free medium composed of a synthetic minimal essential medium and a yeast extract for the propagation of vertebrate cells and a virus production process.
  • a medium formulation composed of a basal cell culture medium comprising a rice peptide and an extract of yeast and an enzymatic digest thereof, and/or a plant lipid for growth of animal cells is disclosed in WO 98/15614.
  • a medium comprising purified soy hydrolysate for the cultivation of recombinant cells is disclosed in WO 01/23527.
  • WO 00/03000 discloses a medium that comprises a soy hydrolysate and a yeast extract, but also requires the presence of recombinant forms of animal proteins, such as growth factors.
  • EP-A-0 481 791 describes a biochemically defined culture medium for culturing engineered CHO cells, which is free from protein, lipid and carbohydrate isolated from an animal source, further comprising a recombinant insulin or insulin analogue, 1% to 0.025% w/v papain digested soy peptone and putrescine.
  • WO 98/08934 describes a serum-free eukaryotic cell culture comprising hydrolyzed soy peptides (1-1000 mg/L), 0.01 to 1 mg/L putrescine and a variety of animal-derived components, including albumin, fetuin, various hormones and other proteins.
  • putrescine is also known to be comprised in standard media like DMEM/Ham's F12 in a concentration of 0.08 mg/L.
  • the plant and/or yeast hydrolysates are undefined mixtures of oligopeptides and other unknown components and contaminants. Moreover, the quality of commercially available lots of hydrolysates varies extremely. As a result, there are large variations in the production of recombinant proteins or viral products (a variation of up to a factor of 3) as a function of the lots of hydrolysates used (“lot-to-lot variation”). This drawback affects the proliferation of the cells as well as the protein expression of each cell.
  • the media known in the state of the art are supplemented with proteins or peptide extracts derived from animals, plants, or yeast; or with recombinant versions of proteins, such as, for example, insulin, insulin like growth factor or other growth factors.
  • a further object of the present invention is to provide methods for cultivating cells in said media as well as methods for efficient expression of recombinant proteins and/or methods for the efficient production of viruses.
  • the addition of at least 0.5 mg/L of a polyamine to cell culture media provides an advantageous effect not only by promoting cell growth but also by increasing the protein and/or virus expression per cell. Said unexpected advantageous effect can be achieved even in oligopeptide-free media.
  • the oligopeptide-free medium according to the present invention allows consistent cell growth and increased yield of desired products, particularly of target proteins such as recombinant proteins and/or viruses, independent of the quality or lot variations of any protein hydrolysates.
  • the specific supplementation of cell culture media with a specific concentration of polyamines acts to increase cell growth, cell specific productivity and final cell density.
  • the media according to the present invention are more favorable for recombinant protein expression, virus production and cell growth rate compared to the media known in the art. Furthermore, the oligopeptide-free medium according to the present invention obviates the addition of protein hydrolysate to the cell culture medium.
  • FIG. 1 shows a graph which describes the effect of the addition of 2.0 mg/L putrescine.2HCl on the volumetric FVIII-CoA productivity, expressed in [Units per Liter per Day], of GD8/6 cells cultivated in BAV-medium over the culture time, expressed in [days].
  • Arrow Day 11: Addition of Putrescine.2HCl (2.0 mg/l)
  • FIG. 2 shows a table which compares the effect of the addition of putrescine optionally in combination with the additional supplementation with Fe (II) and Cu (II) on the volumetric and cell specific productivity (QP, expressed in [Units per Liter per Day], qp, expressed in [mU per 10E06 cells per day]) and on the specific growth rate ⁇ , expressed as specific growth rate per day in [d ⁇ 1 ] of GD8/6 cells cultivated in BAV-medium.
  • QP expressed in [Units per Liter per Day]
  • qp expressed in [mU per 10E06 cells per day]
  • ⁇ expressed as specific growth rate per day in [d ⁇ 1 ] of GD8/6 cells cultivated in BAV-medium.
  • FIG. 3 shows a table which compares the effect of putrescine and/or ornithine on the specific growth rate ( ⁇ absolute, ⁇ relative) and the cell specific productivity (qp absolute, expressed in [mU per 10E06 cells per day], qp relative, expressed in %) of GD8/6 cells cultivated in BAV-medium.
  • FIG. 4 shows a table which compares the effect of putrescine and spermine on the specific growth rate ( ⁇ absolute, ⁇ relative) and the cell specific productivity (qp absolute, qp relative) of GD8/6 cells cultivated in BAV-medium.
  • FIG. 5 shows a table which compares the effect of putrescine and ethanolamine on the specific growth ( ⁇ absolute, ⁇ relative) and the cell specific productivity (qp absolute, qp relative) of GD8/6 cells cultivated in BAV-medium.
  • FIG. 6 shows a graph which describes the effect of the addition of 3.6 mg/L putrescine.2HCl on the average MVA virus titer, expressed in [TCID50/ml ⁇ 10 8 ]. -: without addition of Putrescine, Putr.: with addition of 3.6 mg/L putrescine.2HCl.
  • FIG. 7 shows a graph which describes the effect of the addition of various concentrations of putrescine.2HCl, expressed in [mg/l], on the average MVA virus titer, expressed in [TCID50/ml ⁇ 10 8 ].
  • One aspect of the invention relates to an oligopeptide-free cell culture medium comprising at least 0.5 mg/L of a polyamine.
  • polyamine refers to any of the group of biogenic polyamines, which are organic polycations derived from aromatic or cationic amino acids. Polyamines are composed of carbon, nitrogen, and hydrogen and comprise two or more amino groups. Polyamines have one or more positive charges and a hydrophobic skeleton.
  • the term encompasses, for example, molecules selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, ornithine, and combinations thereof.
  • the oligopeptide-free culture medium comprises ornithine, or putrescine, or spermine, or combinations thereof.
  • the polyamine originates from a source other than a protein hydrolysate. In one embodiment, the polyamine is synthetically produced.
  • the polyamine concentration is at least about 0.5 mg/L, in another embodiment at least about 1 mg/L, in a further embodiment at least about 2 mg/L, in still another embodiment at least 5 mg/L, in yet another embodiment at least 8 mg/L, and in a further embodiment at least 10 mg/L.
  • the polyamine concentration ranges from about 0.5 mg/L to about 30 mg/L, in another embodiment from about 0.5 mg/L to about 20 mg/L, in a further embodiment from about 1.0 mg/L to about 20 mg/L, in a further embodiment from about 2.0 mg/L to about 20 mg/L, in a further embodiment from about 2 mg/L to about 10 mg/L, in an alternative embodiment from about 2 mg/L to about 8 mg/L, and in a further embodiment from about 2 mg/L to about 5 mg/L in the medium.
  • concentrations indicated above are the respective concentrations of pure polyamine. If a polyamine derivative or a polyamine comprising compound is used, the concentration of the polyamine-group is in the above specified ranges. For example, 2 mg/L Putrescine.2HCl is equivalent to a Putrescine concentration of about 1.095 mg/L (without .2HCl).
  • oligopeptide-free cell culture medium refers to a protein-free medium that does not comprise oligopeptides, such as, e.g., oligopeptides derived from a protein hydrolysate. In one embodiment, the medium does not comprise oligopeptides having twenty or more amino acids. In one embodiment of the present invention, the medium does not comprise oligopeptides having fifteen or more amino acids. In another embodiment of the invention, the medium does not comprise oligopeptides having ten or more amino acids.
  • the medium does not comprise oligopeptides having seven or more amino acids, in another embodiment it does not comprise oligopeptides having five or more amino acids, in still another embodiment it does not comprise oligopeptides having three or more amino acids. According to a further embodiment of the present invention, the medium does not comprise oligopeptides having two or more amino acids.
  • the medium according to the invention may optionally comprise glutathione and/or at least one stable form of glutamine, such as, e.g., L-alanyl-L-glutamine.
  • glutathione as used herein describes a tripeptide composed of the amino acids glutamate, cysteine and glycine including the oxidized form of glutathione, i.e. glutathione disulfide, a glutathione dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.
  • the oligopeptide-free cell culture medium does not comprise oligopeptides having three or more amino acids, but may optionally comprise glutathione.
  • the oligopeptide-free cell culture medium does not comprise oligopeptides having two or more amino acids, but may optionally comprise glutathione and/or at least one stable form of glutamine.
  • Typical proteins and/or oligopeptides that are avoided in the media according to the invention are those found in serum and serum-derived substances, such as, e.g., albumin, transferrin, insulin or other growth factors as well as recombinant forms thereof, or oligopeptides from plant or yeast hydrolysates or ultrafiltered forms thereof.
  • the oligopeptide-free culture medium according to the invention may be based on any basal medium, such as DMEM, Ham's F12, Medium 199, McCoy, or RPMI, generally known to a person skilled in the art.
  • the basal medium may comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, and sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell, said amounts being generally known to a person skilled in the art.
  • the medium may comprise auxiliary substances, such as buffer substances, e.g., sodium bicarbonate, antioxidants, stabilisers to counteract mechanical stress, or protease inhibitors.
  • a non-ionic surfactant such as copolymers and/or mixtures of polyethylene glycols and polypropylene glycols (e.g., Pluronic F68®, SERVA) can be added.
  • the polyamine controls DNA- and RNA-synthesis, and/or cell proliferation, and/or cell differentiation, and/or membrane stabilization, and/or antioxidative DNA-protection.
  • the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium increases the protein and/or virus expression in the cultured cells.
  • the protein expression or virus titer in the cultured cells can be increased by at least 50% by the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium. In still another embodiment said increase is at least 60%.
  • the cell specific productivity is increased at least two-fold by the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium; in another embodiment the cell specific productivity is increased at least three-fold.
  • the addition of at least 0.5 mg/L of a polyamine results in an increase in protein expression and/or virus titer to at least 400%; in a further embodiment to at least 500%; in another embodiment to at least 600%; in a further embodiment to at least 700%.
  • the specific growth rate of the cultured cells can be increased by the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium. In a further embodiment, said specific growth rate can be increased by 10%. In still another embodiment, said specific growth rate can be increased by 20%. In yet another embodiment, said specific growth rate can be increased by 50%. In a further embodiment, said specific growth rate can be increased by 70%. In another embodiment, said specific growth rate can be increased by 80%. In still another embodiment, said specific growth rate can be increased by 90%. In yet another embodiment, said specific growth rate can be increased by 100%.
  • the medium is chemically defined.
  • the term “chemically defined” as used herein shall mean, that the medium does not comprise any undefined supplements, such as, for example, extracts of animal components, organs, glands, plants, or yeast. Accordingly, each component of a chemically defined medium is accurately defined.
  • the present invention further relates to a method for cultivating cells, comprising the steps of:
  • the present invention is not limited to any type of cells.
  • Examples of cell types include mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells.
  • the cells may be, for example, stem cells or recombinant cells transformed with a vector for recombinant gene expression, or cells transfected with a virus for producing viral products.
  • the cells may also be for example cells producing a protein of interest without recombinant transformation, e.g., a B-cell producing an antibody, which may be transformed into an immortalized status, e.g., by viral infection like Epstein Barr Virus infection.
  • the cells may also be for example primary cells, e.g., chicken embryo cells, or primary cell lines. Useful are cells that are used for in vitro virus production.
  • useful cells include BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, Per.C6 cells and chicken embryo cells.
  • the cells used according to the present invention may be cultivated, e.g., by a method selected from the group of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostate-cultivation, all of which are generally known in the field.
  • the present invention further relates to a method for expressing at least one protein, such as, e.g., a heterologous or autologous protein or a recombinant protein, comprising the steps of:
  • the medium of step d) is an oligo-peptide-free medium according to the present invention.
  • the cells of the culture of step a) have been grown in an oligopeptide-free cell culture medium according to the present invention.
  • steps a) to d) are conducted in an oligopeptide-free cell culture medium according to the invention.
  • the nucleic acid sequence comprising a sequence coding for at least one protein may be a vector.
  • the vector may be delivered by a virus or may be a plasmid.
  • the nucleic acid sequence coding for the protein may be a specific gene or a biologically functional part thereof.
  • the protein is at least a biologically active part of a blood coagulation factor such as Factor VIII or at least a biologically active part of a protein involved in the production of red blood cells and angiogenesis such as erythropoeitin, or a monoclonal antibody.
  • the nucleic acid sequence comprises a sequence coding for at least one protein selected from the group of coagulation factor VII, coagulation factor VIII, coagulation factor IX, vWF, ADAMTS13, and furin.
  • the nucleic acid further comprises other sequences suitable for a controlled expression of a protein such as promotor sequences, enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to a person skilled in the art.
  • sequences suitable for a controlled expression of a protein such as promotor sequences, enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to a person skilled in the art.
  • the cells are selected from the group of CHO cells, 293 cells, and BHK cells.
  • the following cell lines may be transformed with a recombinant vector for the expression of the respective products: CHO cells for the production of recombinant coagulation factors, for example factor VII, and/or factor VIII, and/or monoclonal antibodies, BHK cells for the production of recombinant erythropoietin, Epstein Barr virus transformed, immortalized human B cells for the production of human antibodies.
  • recombinant coagulation factors for example factor VII, and/or factor VIII, and/or monoclonal antibodies
  • BHK cells for the production of recombinant erythropoietin
  • Epstein Barr virus transformed immortalized human B cells for the production of human antibodies.
  • Useful cell/protein combinations are, for example, CHO cells/coagulation factor VIII, CHO cells/coagulation factor VII, CHO cells/ADAMTS13, CHO cells/furin, and 293 cells/coagulation factor IX.
  • the expression of the at least one protein by cells being cultivated in a medium according to the present invention is increased when compared to the expression of the protein by cells not being cultivated in a medium of the present invention.
  • said expression is increased for at least 10%, according to a further embodiment for at least 50%.
  • the present invention further relates to a method for producing at least one virus or at least one part of a virus, comprising the steps of:
  • the medium of step d) is an oligo-peptide-free medium according to the present invention.
  • the cells of the culture of step a) have been grown in an oligopeptide-free cell culture medium according to the present invention.
  • steps a) to d) are conducted in an oligopeptide-free cell culture medium according to the invention.
  • the virus used in the method according to the invention may be any virus, such as, for example, poxviruses, for example vaccinia or attenuated vaccinia viruses; coronaviruses, for example SARS virus; orthomyxoviruses, for example influenza A or B virus; paramyxoviruses; retroviruses, for example Lenti virus; togaviruses, for example Ross River virus; flaviviruses, for example West Nile virus, Yellow Fever Virus, or FSME virus (i.e. tick borne encephalitis virus); enteroviruses, for example hepatitis A virus; picornaviruses; arenaviruses; herpesviruses'; or adenoviruses.
  • the virus is Modified Vaccinia Virus Ankara (MVA).
  • the virus can be propagated according to the invention for the production of a respective vaccine.
  • the virus may be a wild-type-virus, an attenuated virus, a reassortant virus, or a recombinant virus or combinations thereof, e.g., attenuated and recombinant.
  • an infectious nucleic acid clone may be used instead of actual virions being used to infect cells with a virus.
  • Split virions may also be used instead of actual virions being used to infect cells with a virus.
  • the method for producing a virus may be used for producing immunogenic compositions comprising a virus, a virus antigen, or a virus-like-particle.
  • the cells used in the method for producing a virus according to the present invention may be selected from the group consisting of mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells. In one embodiment, the cells used in the method for producing a virus according to the present invention are selected from the group consisting of Vero cells and chicken embryo cells.
  • Useful combinations of cells with viruses for producing a virus or part of a virus are, for example, Vero cell/attenuated vaccinia, Vero cell/Vaccinia, Vero cell/Hepatitis A, Vero cell/Influenza Virus, Vero cell/West Nile Virus, Vero cell/SARS Virus, Vero cell/Yellow Fever Virus, and chicken embryo cells/FSME virus.
  • the cell/virus combination is chicken embryo cells/Modified Vaccinia Virus Ankara (MVA).
  • Useful cultivation methods include batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostat-cultivation.
  • Oligopeptide-free medium (BAV-medium) was prepared with basal DMEM/HAM's F12 (1:1) comprising inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were L-glutamine (600 mg/L), ascorbic acid (20 ⁇ M), ethanol amine (25 ⁇ M), Synperonic® (SERVA) (0.25 g/L), sodium selenite (50 nM).
  • Factor VIII Factor VIII
  • FIGS. 1 to 5 The activity of Factor VIII (FVIII) was measured by a chromogenic assay (Chromogenic, Sweden).
  • the volumetric productivity (QP) is calculated from the amount of activity units yielded per liter reactor volume per day (U/L/d) in the production system.
  • the cell specific productivity is defined as the specific amount of produced protein (U or ⁇ g) per number of cells per day.
  • Cell cultures of recombinant mammalian cells e.g., CHO-cells stably expressing Factor VIII, such as GD8/6 cells
  • the culture conditions of 37° C., oxygen saturation 20%, and pH 7.0 to 7.1 were kept constant.
  • the cultures were supplied with a constant feed of BAV-medium.
  • GD8/6 cells were grown in chemostat culture in a 10 L bioreactor as described in Example 5 with a continuous feed of BAV-medium for 11 days, resulting in a decreased productivity of ⁇ 100U/L/d.
  • putrescine.2HCl 2 mg/L
  • the volumetric FVIII-expression increased by 800% (cf. FIG. 1 ). Accordingly, putrescine could be clearly identified as the driving factor of cell specific expression for the GD8/6 cell line.
  • GD8/6 cells were grown in chemostat culture in a 10 L bioreactor as described in Example 5, resulting in an average productivity of 271 U/L/D, with low cell specific productivity and specific growth rates.
  • Putrescine.2HCl 2 mg/L
  • the FVIII expression increased to 870 U/L/D, mainly due to an increased cell specific productivity.
  • Additional supplementation with Fe (II) and Cu (II) in a concentration as it is otherwise typically comprised in soy hydrolysates was leading to an increased specific growth rate of approximately 0.60 d ⁇ 1 , and an increase of the cell specific productivity to over 1700 mU/10E06 cells/day could be achieved. Under these conditions a volumetric productivity of over 2685 U/L/D was reached.
  • a further increase of the cell density resulted in a volumetric productivity of over 3000 U/L/D.
  • the maximum volumetric productivity of a soy hydrolysate comprising medium under comparable fermentation conditions was 2000 to 2500 U/L/D, indicating that a chemically defined medium comprising only Putrescine and 2 additional metal ions is superior to any soy hydrolysate comprising medium formulation investigated in this process before (cf. FIG. 2 ).
  • GD8/6 cells from a culture with BAV-medium as described in Example 8 were centrifuged and transferred to Techne Spinner flasks with a working volume of 200 ml and incubated at a cell density of about 1-2E06 cell/ml with defined medium, supplemented with ethanolamine, putrescine, ornithine, and/or spermine as indicated in FIGS. 3, 4 , and 5 .
  • Ornithine which is a precursor of putrescine in the pathway of biogenic amines, could partially substitute putrescine in a concentration-dependent manner.
  • FM medium was prepared with basal M199 medium comprising inorganic salts, amino acids, vitamins and other components (Life technologies, 31150 Powder). Also added were NaHCO3 (ad 4.4 g/L), Gentamycin.SO4 (50 ⁇ g/L) and Neomycin.SO4 (50 ⁇ g/L).
  • CEM was prepared with basal DMEM/HAM's F12 (1:1) comprising inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were NaHCO3 (2 g/L) L-glutamine (600 mg/L), ascorbic acid (20 ⁇ M), ethanol amine (25 ⁇ M), Synperonic ® (SERVA) (0.25 g/L), sodium selenite (50 nM), FeSO4.7H2O (600 ⁇ g/L), Gentamycin.SO4 (50 ⁇ g/L) and Neomycin.SO4 (50 ⁇ g/L). Additionally essential amino acids were supplemented to the cell culture medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
US11/649,694 2006-01-04 2007-01-03 Oligopeptide-free cell culture media Abandoned US20070212770A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/649,694 US20070212770A1 (en) 2006-01-04 2007-01-03 Oligopeptide-free cell culture media
US13/035,696 US20110151512A1 (en) 2006-01-04 2011-02-25 Oligopeptide-free cell culture media
US14/942,771 US9758568B2 (en) 2006-01-04 2015-11-16 Oligopeptide-free cell culture media
US15/670,217 US10696731B2 (en) 2006-01-04 2017-08-07 Oligopeptide-free cell culture media

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75641906P 2006-01-04 2006-01-04
US11/649,694 US20070212770A1 (en) 2006-01-04 2007-01-03 Oligopeptide-free cell culture media

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/035,696 Continuation US20110151512A1 (en) 2006-01-04 2011-02-25 Oligopeptide-free cell culture media

Publications (1)

Publication Number Publication Date
US20070212770A1 true US20070212770A1 (en) 2007-09-13

Family

ID=37942126

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/649,694 Abandoned US20070212770A1 (en) 2006-01-04 2007-01-03 Oligopeptide-free cell culture media
US13/035,696 Abandoned US20110151512A1 (en) 2006-01-04 2011-02-25 Oligopeptide-free cell culture media
US14/942,771 Active US9758568B2 (en) 2006-01-04 2015-11-16 Oligopeptide-free cell culture media
US15/670,217 Active 2027-03-11 US10696731B2 (en) 2006-01-04 2017-08-07 Oligopeptide-free cell culture media

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/035,696 Abandoned US20110151512A1 (en) 2006-01-04 2011-02-25 Oligopeptide-free cell culture media
US14/942,771 Active US9758568B2 (en) 2006-01-04 2015-11-16 Oligopeptide-free cell culture media
US15/670,217 Active 2027-03-11 US10696731B2 (en) 2006-01-04 2017-08-07 Oligopeptide-free cell culture media

Country Status (18)

Country Link
US (4) US20070212770A1 (pt)
EP (4) EP1974014B1 (pt)
JP (6) JP5259418B2 (pt)
KR (2) KR101423344B1 (pt)
CN (2) CN102643777A (pt)
AU (1) AU2007204044B2 (pt)
CA (1) CA2633306A1 (pt)
CY (1) CY1119046T1 (pt)
DK (3) DK1974014T3 (pt)
ES (3) ES2629304T3 (pt)
HK (1) HK1177950A1 (pt)
HU (1) HUE032744T2 (pt)
LT (1) LT1974014T (pt)
PL (3) PL3121266T3 (pt)
PT (3) PT2522717E (pt)
RU (3) RU2486236C2 (pt)
SI (1) SI2522717T1 (pt)
WO (1) WO2007077217A2 (pt)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176269A1 (en) * 2007-12-27 2009-07-09 Baxter International Inc. Cell culture processes
US20090181423A1 (en) * 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
US20090215123A1 (en) * 2008-02-25 2009-08-27 Baxter International Inc. Method for Producing Continuous Cell Lines
WO2010056584A1 (en) * 2008-11-12 2010-05-20 Baxter International Inc. Method of producing serum-free insulin-free factor vii
WO2011014838A1 (en) 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
WO2011035335A2 (en) 2009-09-21 2011-03-24 Baxter International Inc. Stabilized liquid and lyophilized adamts13 formulations
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
WO2012037530A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph
WO2012058480A1 (en) 2010-10-27 2012-05-03 Baxter International Inc. Fviii peptides for immune tolerance induction and immunodiagnostics
WO2012171031A1 (en) 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
WO2014144198A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
KR101594046B1 (ko) * 2008-01-09 2016-02-15 첼카 게엠베하 개선된 배양 배지 첨가제 및 이를 이용한 방법
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
WO2017024062A1 (en) 2015-08-04 2017-02-09 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2019010496A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION
WO2019010497A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
WO2019183290A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
WO2019204734A1 (en) 2018-04-20 2019-10-24 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-il12/il23 antibody compositions
EP3383894B1 (en) 2015-12-02 2020-05-06 CSL Behring Lengnau AG Improved media for the expression of recombinant vitamin k-dependent proteins
WO2020100073A1 (en) 2018-11-13 2020-05-22 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
WO2020160460A1 (en) 2019-02-01 2020-08-06 Baxalta Incorporated Methods of prophylactic treatment using recombinant vwf (rvwf)
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2021050718A1 (en) 2019-09-11 2021-03-18 Baxalta Incorporated Methods of treatment related to complexes of von willebrand factor and complement c1q
WO2021112927A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021158777A1 (en) 2020-02-04 2021-08-12 Baxalta Incorporated Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
CN114075269A (zh) * 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
WO2022159432A1 (en) 2021-01-20 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023167847A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Bioreactor for antibody production

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974014B1 (en) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptide-free cell culture media
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
MX2012012525A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo mejorado.
WO2014062535A1 (en) 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR101641655B1 (ko) * 2014-01-08 2016-07-21 서울대학교산학협력단 스퍼미딘 또는 스퍼민을 이용함으로써 생육 저해제에 대한 내성이 증진된 효모의 배양방법
EP3271324B1 (en) * 2015-03-17 2019-09-04 DSM IP Assets B.V. Process for the preparation of diaminobutane
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
CN108872758B (zh) * 2018-05-10 2019-06-28 江苏大学 一种电子元器件寿命检测装置
US20220177818A1 (en) 2019-04-01 2022-06-09 The Automation Partnership (Cambridge ) Ltd. Operation process for a cell cultivation system
JPWO2021090888A1 (pt) * 2019-11-05 2021-05-14
CN113151183A (zh) * 2021-04-21 2021-07-23 赵峻岭 一种促进蛋白表达的培养基添加物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
US6100061A (en) * 1997-06-20 2000-08-08 Immuno Aktiengesellschaft Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US20030017548A1 (en) * 2001-03-29 2003-01-23 Terence Martin Gastrokines and derived peptides including inhibitors
US20030073116A1 (en) * 2001-08-16 2003-04-17 Regents Of The University Of Michigan ADAMTS13 genes and proteins and variants, and uses thereof
US20030104527A1 (en) * 2001-12-03 2003-06-05 National Research Council Of Canada Methylotrophic bacterium for the production of recombinant proteins and other products
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT165999B (de) 1947-06-26 1950-05-25 Delle Atel Const Electr Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
DK207980A (da) * 1980-05-13 1981-11-14 Novo Industri As Fremgangsmaade til fremstilling af et skumnings- eller emulgeringsmiddel paa sojaproteinbasis
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
DE3787805T2 (de) 1986-08-04 1994-02-10 Univ New South Wales Kensingto Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
AU627427B2 (en) 1987-06-30 1992-08-27 Amgen, Inc. Production of kallikrein
JP2507882B2 (ja) 1988-02-17 1996-06-19 工業技術院長 外部増殖因子非依存性増殖良好細胞株の製造法
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AU653927B2 (en) 1990-01-22 1994-10-20 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Co-independent growth medium for maintenance and propagation of cells
JP2844484B2 (ja) 1990-02-22 1999-01-06 味の素株式会社 組換え蛋白質の生産方法
JP2859679B2 (ja) 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
JP2696001B2 (ja) 1991-04-15 1998-01-14 財団法人化学及血清療法研究所 組換え蛋白質産生用培地
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2053433C (en) 1990-10-19 1997-03-25 Michael Joseph Garvey Detergent compositions
JPH04228066A (ja) 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
JPH05123178A (ja) 1991-11-01 1993-05-21 Ajinomoto Co Inc Ｌ−フエニルアラニンの製造法
AU7895898A (en) 1993-04-26 1998-10-08 Hans Wolf Mammal cell lines and method of obtaining glycoproteins
DE4313620A1 (de) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
JP2766165B2 (ja) 1993-08-02 1998-06-18 株式会社バイオポリマー・リサーチ バクテリアセルロースの製造方法
EP0653487A1 (de) 1993-11-07 1995-05-17 Ferruccio Dr. Messi Serum- und proteinfrei wachsende Zellen
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
EP0733100A1 (de) 1994-09-09 1996-09-25 Wolfgang A. Renner Chemisches verfahren zur förderung der proliferation von tierischen zellen
WO1996015231A2 (en) 1994-11-10 1996-05-23 Immuno Aktiengesellschaft Method for producing biologicals in protein-free culture
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
WO1996018734A1 (en) 1994-12-16 1996-06-20 Novartis Ag Production of recombinant secretory component
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
DE69608668T2 (de) 1995-02-23 2001-02-01 Quest Int Peptide für gewebe- und zellkulturmedien
WO1996040866A1 (en) 1995-06-07 1996-12-19 Novartis Ag Serum-free media for primitive hematopoietic cells and methods of use thereof
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
WO1998008935A1 (en) 1996-08-30 1998-03-05 The University Of North Carolina At Chapel Hill Immortalized human hepatic cell line
JP4543402B2 (ja) 1996-10-10 2010-09-15 ライフ テクノロジーズ コーポレーション 植物由来栄養素を含む動物細胞培養培地
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
EP2199382A3 (en) 1997-05-28 2010-09-22 Novartis Vaccines and Diagnostics S.r.l. Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AU754619B2 (en) 1997-07-23 2002-11-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
CA2309258C (en) 1997-11-20 2012-05-01 Weyerhaeuser Company Nutritive media and manufactured seeds comprising same
AU2112199A (en) * 1998-01-12 1999-07-26 Betagene, Inc. Recombinant cell lines for drug screening
FR2775983B1 (fr) 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
WO1999057246A1 (en) 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
JP4266055B2 (ja) 1999-03-04 2009-05-20 雪印乳業株式会社 ポリアミン組成物の製造法
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2003506077A (ja) 1999-08-05 2003-02-18 バクスター アクチェンゲゼルシャフト 組換え安定細胞クローン、その産生およびその使用
IL148060A0 (en) 1999-08-25 2002-09-12 Immunex Corp Compositions and methods for improved cell culture
DE60139026D1 (de) 2000-09-25 2009-07-30 Polymun Scient Immunbio Forsch Lebender influenza impfstoff und verfahren zu seiner herstellung
EP1208966A1 (en) 2000-11-27 2002-05-29 Cheng-Kun Liao Manufacturing process of patio tabletop glass with broken protection
DE10059175A1 (de) 2000-11-29 2002-06-20 Siemens Ag Verfahren und Vorrichtung zur Anrufumleitung mittels eines Stellvertreters in einem Kommunikationssystem
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
HUP0402158A2 (hu) 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
DE10161412A1 (de) * 2001-12-13 2003-07-03 Aventis Pharma Gmbh Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
FR2846005B1 (fr) 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour milieu biologique comprenant de l'erythorbate de sodium
FR2846004B1 (fr) 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol
DE10333675A1 (de) 2003-07-24 2005-03-03 Aventis Pharma Deutschland Gmbh Perfusionsverfahren für die Produktion von Erythropoietin
JP4740138B2 (ja) 2003-10-10 2011-08-03 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2006050050A2 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1974014B1 (en) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptide-free cell culture media

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
US6100061A (en) * 1997-06-20 2000-08-08 Immuno Aktiengesellschaft Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
US20030017548A1 (en) * 2001-03-29 2003-01-23 Terence Martin Gastrokines and derived peptides including inhibitors
US20030073116A1 (en) * 2001-08-16 2003-04-17 Regents Of The University Of Michigan ADAMTS13 genes and proteins and variants, and uses thereof
US20030104527A1 (en) * 2001-12-03 2003-06-05 National Research Council Of Canada Methylotrophic bacterium for the production of recombinant proteins and other products

Cited By (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359629B2 (en) 2007-12-27 2016-06-07 Baxalta Incorporated Cell culture processes
EP2574677A1 (en) 2007-12-27 2013-04-03 Baxter International Inc. Cell culture processes
EP3255152A1 (en) 2007-12-27 2017-12-13 Baxalta GmbH Cell culture processes
US20090176269A1 (en) * 2007-12-27 2009-07-09 Baxter International Inc. Cell culture processes
EP2574676A1 (en) 2007-12-27 2013-04-03 Baxter International Inc. Cell culture processes
US20090181423A1 (en) * 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
US9127264B2 (en) 2007-12-31 2015-09-08 Baxalta Incorporated Substantially animal protein-free recombinant furin and methods for producing the same
US20110076719A1 (en) * 2007-12-31 2011-03-31 Baxter International Inc. Substantially Animal Protein-Free Recombinant Furin and Methods for Producing the Same
KR101594046B1 (ko) * 2008-01-09 2016-02-15 첼카 게엠베하 개선된 배양 배지 첨가제 및 이를 이용한 방법
US9388380B2 (en) 2008-02-25 2016-07-12 Nanotherapeutics, Inc. Method for producing continuous cell lines
US8865450B2 (en) 2008-02-25 2014-10-21 Baxter International Inc. Method for producing continuous cell lines
US20090215123A1 (en) * 2008-02-25 2009-08-27 Baxter International Inc. Method for Producing Continuous Cell Lines
WO2010056584A1 (en) * 2008-11-12 2010-05-20 Baxter International Inc. Method of producing serum-free insulin-free factor vii
US11254921B2 (en) 2009-07-31 2022-02-22 Takeda Pharmaceutical Company Limited ADAMTS13 protein cell culture supernatant
US20110086413A1 (en) * 2009-07-31 2011-04-14 Baxter International Inc. Cell Culture Medium For ADAMTS Protein Expression
WO2011014838A1 (en) 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
US10072254B2 (en) 2009-07-31 2018-09-11 Baxalta Incorporated Cell culture methods for expressing ADAMTS13 protein
US8759026B2 (en) 2009-07-31 2014-06-24 Baxter International Inc. Methods for increasing recovery of an ADAMTS activity from a cell culture supernatant
US10724024B2 (en) 2009-07-31 2020-07-28 Baxalta Incorporated Cell culture methods for expressing ADAMTS protein
US8313926B2 (en) 2009-07-31 2012-11-20 Baxter International Inc. Methods for expressing ADAMTS proteins in cell culture medium supplemented with zinc
US9127265B2 (en) 2009-07-31 2015-09-08 Baxalta Incorporated Cell culture medium for ADAMTS protein expression
US9441216B2 (en) 2009-07-31 2016-09-13 Baxalta Incorporated Cell culture medium for ADAMTS protein expression
EP3167897A1 (en) 2009-09-21 2017-05-17 Baxalta GmbH Stabilized liquid and lyophilized adamts13 formulations
EP3834841A1 (en) 2009-09-21 2021-06-16 Takeda Pharmaceutical Company Limited Stabilized liquid and lyophilized adamts13 formulations
EP4218797A1 (en) 2009-09-21 2023-08-02 Takeda Pharmaceutical Company Limited Stabilized liquid and lyophilized adamts13 formulations
WO2011035335A2 (en) 2009-09-21 2011-03-24 Baxter International Inc. Stabilized liquid and lyophilized adamts13 formulations
US9458222B2 (en) * 2010-07-08 2016-10-04 Baxalta Incorporated Method of producing recombinant ADAMTS13 in cell culture
EP3909977A1 (en) 2010-07-08 2021-11-17 Takeda Pharmaceutical Company Limited Method of producing recombinant adamts13 in cell culture
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
US9409971B2 (en) 2010-07-08 2016-08-09 Baxalta Incorporated Method of producing recombinant high molecular weight vWF in cell culture
EP3064508A1 (en) 2010-07-08 2016-09-07 Baxalta GmbH Method of producing recombinant high molecular weight vwf in cell culture
WO2012006591A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
US20120034674A1 (en) * 2010-07-08 2012-02-09 Baxter Healthcare S.A. Method of producing recombinant adamts13 in cell culture
US11780904B2 (en) 2010-07-08 2023-10-10 Takeda Pharmaceutical Company Limited Method of producing recombinant high molecular weight vWF in cell culture
US9834591B2 (en) 2010-07-08 2017-12-05 Baxalta Incorporated Method of producing recombinant high molecular weight vWF in cell culture
US10100099B2 (en) 2010-07-08 2018-10-16 Baxalta Incorporated Method of producing recombinant high molecular weight vWF in cell culture
US10822394B2 (en) 2010-07-08 2020-11-03 Baxalta GmbH Method of producing recombinant high molecular weight vWF in cell culture
EP3392271A1 (en) 2010-07-08 2018-10-24 Baxalta GmbH Method of producing recombinant adamts13 in cell culture
EP3626736A1 (en) 2010-07-08 2020-03-25 Baxalta GmbH Method of producing recombinant high molecular weight vwf in cell culture
US8852888B2 (en) 2010-07-08 2014-10-07 Baxter International Inc. Method of producing recombinant high molecular weight vWF in cell culture
WO2012037530A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph
EP4289445A2 (en) 2010-09-17 2023-12-13 Takeda Pharmaceutical Company Limited Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
WO2012037534A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
WO2012058480A1 (en) 2010-10-27 2012-05-03 Baxter International Inc. Fviii peptides for immune tolerance induction and immunodiagnostics
EP3260132A1 (en) 2010-10-27 2017-12-27 Baxalta GmbH Fviii peptides for immune tolerance induction and immunodiagnostics
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505834B2 (en) 2011-04-27 2016-11-29 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP3412305A1 (en) 2011-06-10 2018-12-12 Baxalta GmbH Treatment of coagulation disease by administration of recombinant vwf
EP3858375A1 (en) 2011-06-10 2021-08-04 Takeda Pharmaceutical Company Limited Treatment of coagulation disease by administration of recombinant vwf
WO2012171031A1 (en) 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
US9957318B2 (en) 2012-04-20 2018-05-01 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US11332771B2 (en) 2013-03-15 2022-05-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
EP4159841A1 (en) 2013-03-15 2023-04-05 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US11970724B2 (en) 2013-03-15 2024-04-30 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
EP3378932A1 (en) 2013-03-15 2018-09-26 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
EP3919611A1 (en) 2013-03-15 2021-12-08 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
WO2014144198A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
US11312936B2 (en) 2015-08-04 2022-04-26 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
WO2017024062A1 (en) 2015-08-04 2017-02-09 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
EP3383894B1 (en) 2015-12-02 2020-05-06 CSL Behring Lengnau AG Improved media for the expression of recombinant vitamin k-dependent proteins
CN114075269A (zh) * 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
WO2019010496A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION
WO2019010497A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
US10905746B2 (en) 2017-07-07 2021-02-02 Baxalta GmbH Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US11529395B2 (en) 2017-07-07 2022-12-20 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US10934340B2 (en) 2018-03-21 2021-03-02 Baxalta Incorporated Separation of VWF and VWF propeptide by chromatographic methods
WO2019183290A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
WO2019204721A1 (en) 2018-04-20 2019-10-24 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for produring anti-tnf antibody compositions
WO2019204734A1 (en) 2018-04-20 2019-10-24 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-il12/il23 antibody compositions
US11634499B2 (en) 2018-11-13 2023-04-25 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
WO2020100073A1 (en) 2018-11-13 2020-05-22 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
WO2020160460A1 (en) 2019-02-01 2020-08-06 Baxalta Incorporated Methods of prophylactic treatment using recombinant vwf (rvwf)
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2021050718A1 (en) 2019-09-11 2021-03-18 Baxalta Incorporated Methods of treatment related to complexes of von willebrand factor and complement c1q
US11098311B2 (en) 2019-12-06 2021-08-24 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021112926A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11186625B2 (en) 2019-12-06 2021-11-30 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021112927A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
US11104715B2 (en) 2019-12-06 2021-08-31 Regeneran Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US11098112B2 (en) 2019-12-06 2021-08-24 Regeneron Pharmnaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11286290B2 (en) 2019-12-06 2022-03-29 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11299532B2 (en) 2019-12-06 2022-04-12 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11306135B2 (en) 2019-12-06 2022-04-19 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021112924A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
US11053280B2 (en) 2019-12-06 2021-07-06 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021112928A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
US11407813B2 (en) 2019-12-06 2022-08-09 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11440950B2 (en) 2019-12-06 2022-09-13 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11459373B2 (en) 2019-12-06 2022-10-04 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11459374B2 (en) 2019-12-06 2022-10-04 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11472861B2 (en) 2019-12-06 2022-10-18 Regeneron Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US11485770B2 (en) 2019-12-06 2022-11-01 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11505593B2 (en) 2019-12-06 2022-11-22 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11505594B2 (en) 2019-12-06 2022-11-22 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11174283B2 (en) 2019-12-06 2021-11-16 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11535663B2 (en) 2019-12-06 2022-12-27 Regeneron Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US11542317B1 (en) 2019-12-06 2023-01-03 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11548932B2 (en) 2019-12-06 2023-01-10 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11753459B2 (en) 2019-12-06 2023-09-12 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11732025B2 (en) 2019-12-06 2023-08-22 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021112929A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021112925A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
US11649273B2 (en) 2019-12-06 2023-05-16 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021112923A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmacetucals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021158777A1 (en) 2020-02-04 2021-08-12 Baxalta Incorporated Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
WO2022159432A1 (en) 2021-01-20 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023167847A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Bioreactor for antibody production
WO2023167850A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2023167863A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2023167855A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2023167852A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production
WO2023167871A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2023167857A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Also Published As

Publication number Publication date
HK1177950A1 (en) 2013-08-30
JP2009521941A (ja) 2009-06-11
DK2522717T3 (da) 2014-04-22
CY1119046T1 (el) 2018-01-10
KR101423344B1 (ko) 2014-07-30
PL2522717T3 (pl) 2014-08-29
RU2017144220A (ru) 2019-06-18
PT3121266T (pt) 2020-05-19
US20160068587A1 (en) 2016-03-10
PT2522717E (pt) 2014-05-15
KR20130100224A (ko) 2013-09-09
JP2017055770A (ja) 2017-03-23
DK1974014T3 (en) 2017-06-19
EP1974014B1 (en) 2017-04-19
ES2474573T3 (es) 2014-07-09
RU2642269C9 (ru) 2018-10-31
RU2008131953A (ru) 2010-02-10
DK3121266T3 (da) 2020-05-11
RU2758802C2 (ru) 2021-11-02
JP2013106616A (ja) 2013-06-06
PL1974014T3 (pl) 2017-09-29
PT1974014T (pt) 2017-05-26
EP1974014A2 (en) 2008-10-01
US9758568B2 (en) 2017-09-12
CN102643777A (zh) 2012-08-22
HUE032744T2 (en) 2017-10-30
EP3653699A1 (en) 2020-05-20
ES2790887T3 (es) 2020-10-29
AU2007204044A1 (en) 2007-07-12
AU2007204044B2 (en) 2012-09-27
WO2007077217A2 (en) 2007-07-12
KR20080083197A (ko) 2008-09-16
JP2018075032A (ja) 2018-05-17
WO2007077217A3 (en) 2007-11-08
EP2522717B1 (en) 2014-04-02
JP2015006209A (ja) 2015-01-15
ES2629304T3 (es) 2017-08-08
US20170362300A1 (en) 2017-12-21
JP5259418B2 (ja) 2013-08-07
EP3121266B1 (en) 2020-02-26
EP2522717A1 (en) 2012-11-14
EP3121266A1 (en) 2017-01-25
JP7134157B2 (ja) 2022-09-09
LT1974014T (lt) 2017-11-27
JP2020028307A (ja) 2020-02-27
CN101360820A (zh) 2009-02-04
EP3121266B8 (en) 2020-04-22
RU2017144220A3 (pt) 2021-03-01
RU2486236C2 (ru) 2013-06-27
US20110151512A1 (en) 2011-06-23
US10696731B2 (en) 2020-06-30
JP6567490B2 (ja) 2019-08-28
RU2642269C2 (ru) 2018-01-24
RU2013112019A (ru) 2014-09-27
KR101422435B1 (ko) 2014-07-22
SI2522717T1 (sl) 2014-05-30
PL3121266T3 (pl) 2020-07-13
CA2633306A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
US10696731B2 (en) Oligopeptide-free cell culture media
US20180023048A1 (en) Animal protein-free media for cultivation of cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;REEL/FRAME:019528/0581;SIGNING DATES FROM 20070427 TO 20070514

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;REEL/FRAME:019528/0581;SIGNING DATES FROM 20070427 TO 20070514

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION